Risankizumab in psoriasis: prior biologics failure does not impact on short-term effectiveness

Expert Opin Biol Ther. 2022 Jan;22(1):105-107. doi: 10.1080/14712598.2022.2012567. Epub 2021 Dec 12.
No abstract available

Keywords: Psoriasis; biologics; effectiveness; interleukin-23; real-world data; risankizumab; therapy-systemic.

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Biological Products* / adverse effects
  • Humans
  • Psoriasis* / drug therapy

Substances

  • Antibodies, Monoclonal
  • Biological Products
  • risankizumab